CJC-1295 (no DAC) 5 mg

Description

Pulsatile GH signaling research peptide

CJC-1295 (no DAC) is a synthetic analogue of growth hormone–releasing hormone (GHRH) investigated for its interaction with endogenous growth hormone secretion pathways and hypothalamic–pituitary endocrine signaling mechanisms. It belongs to the GHRH analogue research class and is commonly studied in laboratory models examining pulsatile GH release, IGF-1 axis modulation, and endocrine pathway regulation.

Researchers are particularly interested in CJC-1295 without DAC because it is designed to preserve shorter-duration signaling dynamics compared to long-acting DAC-modified variants. Experimental models have explored its role in physiologic pulsatile GH secretion patterns and comparative endocrine signaling studies involving GHRH-mediated pathway activation.

CJC-1295 is frequently investigated alongside growth hormone secretagogues such as Ipamorelin in research models studying synergistic GH-axis modulation and coordinated endocrine pathway interaction. Compared to GHRP compounds including GHRP-2 and GHRP-6, CJC-1295 primarily acts through GHRH receptor–mediated signaling rather than ghrelin receptor activation.

For a broader overview of growth hormone secretagogues, pulsatile GH signaling, and GHRH analogue research compounds, see our Growth hormone peptides research guide.

Research applications (investigational)

CJC-1295 (no DAC) has been investigated in preclinical and experimental settings for its involvement in:

• Growth hormone–releasing hormone (GHRH) receptor signaling
• Pulsatile endogenous GH release mechanisms
• GH/IGF-1 axis modulation research
• Hypothalamic–pituitary endocrine pathway models
• Comparative analysis of GHRH and GHRP compounds
• Endocrine signaling synchronization studies
• Peptide-mediated metabolic and recovery-related pathway interaction

These areas reflect ongoing scientific investigation into endocrine and peptide signaling pathways rather than established applications.

Product characteristics

Purity: ≥ 98% (HPLC)
Appearance: white lyophilized powder
Molecular formula: C₁₅₄H₂₅₅N₄₅O₄₃
Molecular weight: 3424.95
Sequence: Gly-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Storage: store lyophilized powder at -20°C, protect from light and moisture. Reconstituted solution should be kept at 2–8°C and used within a short period.

Why choose our CJC-1295 (no DAC)?

≥ 98% purity verified by HPLC.
Produced in GMP-compliant facilities under strict QC protocols.
Each batch carefully lab tested after production (Certificate of Analysis available under product images).
Freeze-dried (lyophilized) for maximum stability and extended shelf life.
Sealed in sterile vials, ready for reconstitution.
Compatible with standard peptide reconstitution protocols using bacteriostatic water.

Selected research references

• Teichman SL et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295.” Journal of Clinical Endocrinology & Metabolism, 2006.
• Modlin IM et al. “Current status of the therapeutic use of growth hormone, GH-releasing hormone, and GH secretagogues.” Clinical Therapeutics, 2010.
• Alba M et al. “Continuous stimulation of the growth hormone axis by CJC-1295.” Endocrine Practice, 2005.
• Smith RG et al. “Growth hormone secretagogues: physiology and clinical relevance.” Trends in Endocrinology & Metabolism, 2005.

Related research context

CJC-1295 belongs to the GHRH analogue and growth hormone signaling research class, which includes peptides investigated for endocrine regulation, GH-axis modulation, and pulsatile hormone release mechanisms.
For a broader overview of GH signaling pathways and comparative peptide mechanisms, see our Growth hormone peptides research guide.
Researchers studying GH-axis interaction may also examine:

Ipamorelin
GHRP-2
GHRP-6

Browse all compounds in the Growth hormone secretagogues category.
Researchers investigating endocrine regulation may also explore compounds in the Metabolic research category, including GLP-1 and multi-pathway incretin agonists.

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer
This product is sold for research purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Buyer assumes full responsibility for proper handling and use.